330 related articles for article (PubMed ID: 23206899)
1. Dual inhibition of Janus and Src family kinases by novel indirubin derivative blocks constitutively-activated Stat3 signaling associated with apoptosis of human pancreatic cancer cells.
Nam S; Wen W; Schroeder A; Herrmann A; Yu H; Cheng X; Merz KH; Eisenbrand G; Li H; Yuan YC; Jove R
Mol Oncol; 2013 Jun; 7(3):369-78. PubMed ID: 23206899
[TBL] [Abstract][Full Text] [Related]
2. Sustained Src inhibition results in signal transducer and activator of transcription 3 (STAT3) activation and cancer cell survival via altered Janus-activated kinase-STAT3 binding.
Sen B; Saigal B; Parikh N; Gallick G; Johnson FM
Cancer Res; 2009 Mar; 69(5):1958-65. PubMed ID: 19223541
[TBL] [Abstract][Full Text] [Related]
3. MLS-2384, a new 6-bromoindirubin derivative with dual JAK/Src kinase inhibitory activity, suppresses growth of diverse cancer cells.
Liu L; Gaboriaud N; Vougogianopoulou K; Tian Y; Wu J; Wen W; Skaltsounis L; Jove R
Cancer Biol Ther; 2014 Feb; 15(2):178-84. PubMed ID: 24100507
[TBL] [Abstract][Full Text] [Related]
4. Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects.
Johnson FM; Saigal B; Tran H; Donato NJ
Clin Cancer Res; 2007 Jul; 13(14):4233-44. PubMed ID: 17634553
[TBL] [Abstract][Full Text] [Related]
5. 6-Bromoindirubin-3'-oxime inhibits JAK/STAT3 signaling and induces apoptosis of human melanoma cells.
Liu L; Nam S; Tian Y; Yang F; Wu J; Wang Y; Scuto A; Polychronopoulos P; Magiatis P; Skaltsounis L; Jove R
Cancer Res; 2011 Jun; 71(11):3972-9. PubMed ID: 21610112
[TBL] [Abstract][Full Text] [Related]
6. 17-hydroxy-jolkinolide B inhibits signal transducers and activators of transcription 3 signaling by covalently cross-linking Janus kinases and induces apoptosis of human cancer cells.
Wang Y; Ma X; Yan S; Shen S; Zhu H; Gu Y; Wang H; Qin G; Yu Q
Cancer Res; 2009 Sep; 69(18):7302-10. PubMed ID: 19706767
[TBL] [Abstract][Full Text] [Related]
7. Enhanced sensitivity of pancreatic cancer cells to concurrent inhibition of aberrant signal transducer and activator of transcription 3 and epidermal growth factor receptor or Src.
Jaganathan S; Yue P; Turkson J
J Pharmacol Exp Ther; 2010 May; 333(2):373-81. PubMed ID: 20100905
[TBL] [Abstract][Full Text] [Related]
8. A novel 7-bromoindirubin with potent anticancer activity suppresses survival of human melanoma cells associated with inhibition of STAT3 and Akt signaling.
Liu L; Kritsanida M; Magiatis P; Gaboriaud N; Wang Y; Wu J; Buettner R; Yang F; Nam S; Skaltsounis L; Jove R
Cancer Biol Ther; 2012 Nov; 13(13):1255-61. PubMed ID: 22895078
[TBL] [Abstract][Full Text] [Related]
9. Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases.
Murone M; Vaslin Chessex A; Attinger A; Ramachandra R; Shetty SJ; Daginakatte G; Sengupta S; Marappan S; Dhodheri S; Rigotti S; Bachhav Y; Brienza S; Traxler P; Lang M; Aguet M; Zoete V; Michielin O; Nicholas C; Johnson FM; Ramachandra M; McAllister A
Mol Cancer Ther; 2016 Oct; 15(10):2334-2343. PubMed ID: 27439479
[TBL] [Abstract][Full Text] [Related]
10. Janus kinases and Src family kinases in the regulation of EGF-induced vimentin expression in MDA-MB-468 breast cancer cells.
Stewart TA; Azimi I; Brooks AJ; Thompson EW; Roberts-Thomson SJ; Monteith GR
Int J Biochem Cell Biol; 2016 Jul; 76():64-74. PubMed ID: 27163529
[TBL] [Abstract][Full Text] [Related]
11. Parthenolide Inhibits STAT3 Signaling by Covalently Targeting Janus Kinases.
Liu M; Xiao C; Sun M; Tan M; Hu L; Yu Q
Molecules; 2018 Jun; 23(6):. PubMed ID: 29921758
[TBL] [Abstract][Full Text] [Related]
12. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells.
Garcia R; Bowman TL; Niu G; Yu H; Minton S; Muro-Cacho CA; Cox CE; Falcone R; Fairclough R; Parsons S; Laudano A; Gazit A; Levitzki A; Kraker A; Jove R
Oncogene; 2001 May; 20(20):2499-513. PubMed ID: 11420660
[TBL] [Abstract][Full Text] [Related]
13. Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis.
Nagaraj NS; Smith JJ; Revetta F; Washington MK; Merchant NB
Mol Cancer Ther; 2010 Aug; 9(8):2322-32. PubMed ID: 20682659
[TBL] [Abstract][Full Text] [Related]
14. Targeting Upstream Kinases of STAT3 in Human Medulloblastoma Cells.
Wei J; Ma L; Li C; Pierson CR; Finlay JL; Lin J
Curr Cancer Drug Targets; 2019; 19(7):571-582. PubMed ID: 30332965
[TBL] [Abstract][Full Text] [Related]
15. Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer.
Wen W; Wu J; Liu L; Tian Y; Buettner R; Hsieh MY; Horne D; Dellinger TH; Han ES; Jove R; Yim JH
Mol Cancer; 2015 May; 14():100. PubMed ID: 25928246
[TBL] [Abstract][Full Text] [Related]
16. Brevilin A, a novel natural product, inhibits janus kinase activity and blocks STAT3 signaling in cancer cells.
Chen X; Du Y; Nan J; Zhang X; Qin X; Wang Y; Hou J; Wang Q; Yang J
PLoS One; 2013; 8(5):e63697. PubMed ID: 23704931
[TBL] [Abstract][Full Text] [Related]
17. Anti-angiogenic activity of thienopyridine derivative LCB03-0110 by targeting VEGFR-2 and JAK/STAT3 Signalling.
Kim BH; Lee Y; Yoo H; Cui M; Lee S; Kim SY; Cho JU; Lee H; Yang BS; Kwon YG; Choi S; Kim TY
Exp Dermatol; 2015 Jul; 24(7):503-9. PubMed ID: 25808463
[TBL] [Abstract][Full Text] [Related]
18. γ-Tocotrienol is a novel inhibitor of constitutive and inducible STAT3 signalling pathway in human hepatocellular carcinoma: potential role as an antiproliferative, pro-apoptotic and chemosensitizing agent.
Rajendran P; Li F; Manu KA; Shanmugam MK; Loo SY; Kumar AP; Sethi G
Br J Pharmacol; 2011 May; 163(2):283-98. PubMed ID: 21198544
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib induces apoptosis in HL60 cells by inhibiting Src kinase-mediated STAT3 phosphorylation.
Zhao W; Zhang T; Qu B; Wu X; Zhu X; Meng F; Gu Y; Shu Y; Shen Y; Sun Y; Xu Q
Anticancer Drugs; 2011 Jan; 22(1):79-88. PubMed ID: 20881478
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms underlying the cytotoxicity of a novel quinazolinedione-based redox modulator, QD232, in pancreatic cancer cells.
Pathania D; Kuang Y; Sechi M; Neamati N
Br J Pharmacol; 2015 Jan; 172(1):50-63. PubMed ID: 25047070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
